Associations between demographic and clinical characteristics and death among 6624 persons with NSHA in the United States, 2010-2018
| . | Total, n (%) . | Death, n (%) . | Mortality rate* . | Bivariate analysis . | Multivariable analysis† . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics . | Mortality risk ratio . | 95% CI . | Hazard ratio . | 95% CI . | |||||
| Age, y‡ | 2.1§ | 2.0-2.4 | |||||||
| 0-9 | 968 (14.6) | 0 (0) | 0 | N/A | N/A | ||||
| 10-19 | 1612 (24.3) | 6 (4.4) | 0.4 | 1|| | |||||
| 20-29 | 1269 (19.2) | 1 (0.7) | 0.1 | 0.2 | 0.03-1.7 | ||||
| 30-39 | 842 (12.7) | 8 (5.9) | 1.1 | 2.6 | 0.9-7.4 | ||||
| 40-49 | 586 (8.9) | 17 (12.5) | 3.3 | 7.9 | 3.1-20.0 | ||||
| 50-59 | 538 (8.1) | 24 (17.7) | 5 | 12.1 | 5.0-29.7 | ||||
| 60-69 | 446 (6.7) | 33 (24.3) | 8.4 | 20.4 | 8.6-48.7 | ||||
| 70+ | 363 (5.5) | 47 (34.6) | 14.9 | 36 | 15.3-84.1 | ||||
| Sex | |||||||||
| Female | 930 (14.0) | 5 (3.7) | 0.6 | 1 | Ref | ||||
| Male | 5694 (86.0) | 131 (96.3) | 2.7 | 4.4 | 1.8-10.8 | 2.6 | 1.0-6.4 | ||
| Race | |||||||||
| White | 5499 (83.0) | 124 (91.2) | 2.7 | 1 | Ref | ||||
| Black | 543 (8.2) | 8 (5.9) | 1.8 | 0.7 | 0.3-1.4 | 0.8¶ | 0.4-1.4 | ||
| Other/unknown | 582 (8.8) | 4 (2.9) | 0.8 | 0.3 | 0.1-0.8 | ||||
| Ethnicity | |||||||||
| Hispanic | 1199 (18.1) | 12 (8.8) | 1.2 | 1 | Ref | ||||
| Non-Hispanic | 5345 (80.7) | 123 (90.4) | 2.7 | 2.3 | 1.2-4.1 | 0.6 | 0.4-1.2 | ||
| Unknown | 80 (1.1) | 1 (0.7) | 1.6 | 1.3 | 0.2-12.2 | ||||
| Severity | |||||||||
| Mild | 4720 (71.3) | 94 (69.1) | 2.3 | 1 | Ref | ||||
| Moderate | 1904 (28.7) | 42 (30.9) | 2.7 | 1.1 | 0.9-1.9 | 0.9 | 0.6-1.3 | ||
| Inhibitor | |||||||||
| No | 6453 (97.4) | 133 (97.8) | 2.4 | 1 | Ref | ||||
| Yes | 171 (2.6) | 3 (2.2) | 2 | 0.8 | 0.3-2.6 | 0.7 | 0.2-2.3 | ||
| Hepatitis B | |||||||||
| No | 6519 (98.4) | 133 (97.8) | 2.4 | 1 | Ref | ||||
| Yes | 105 (1.6) | 3 (2.2) | 3.3 | 1.4 | 0.4-4.3 | 0.3 | 0.1-1.0 | ||
| Hepatitis C | |||||||||
| No | 6001 (90.6) | 78 (57.4) | 1.5 | 1 | Ref | ||||
| Yes | 623 (9.4) | 58 (42.7) | 10.8 | 7 | 5.0-9.8 | 2.2 | 1.5-3.1 | ||
| HIV | |||||||||
| No | 6454 (97.4) | 114 (83.8) | 2.1 | 1 | Ref | ||||
| Yes | 170 (2.6) | 22 (16.2) | 15.2 | 7.3 | 4.6-11.5 | 3.6 | 2.2-6.0 | ||
| FVIII exposure# | |||||||||
| No | 555 (8.4) | 3 (2.2) | |||||||
| Yes | 5122 (77.3) | 99 (72.8) | |||||||
| Unknown | 947 (14.3) | 34 (25.0) | |||||||
| . | Total, n (%) . | Death, n (%) . | Mortality rate* . | Bivariate analysis . | Multivariable analysis† . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics . | Mortality risk ratio . | 95% CI . | Hazard ratio . | 95% CI . | |||||
| Age, y‡ | 2.1§ | 2.0-2.4 | |||||||
| 0-9 | 968 (14.6) | 0 (0) | 0 | N/A | N/A | ||||
| 10-19 | 1612 (24.3) | 6 (4.4) | 0.4 | 1|| | |||||
| 20-29 | 1269 (19.2) | 1 (0.7) | 0.1 | 0.2 | 0.03-1.7 | ||||
| 30-39 | 842 (12.7) | 8 (5.9) | 1.1 | 2.6 | 0.9-7.4 | ||||
| 40-49 | 586 (8.9) | 17 (12.5) | 3.3 | 7.9 | 3.1-20.0 | ||||
| 50-59 | 538 (8.1) | 24 (17.7) | 5 | 12.1 | 5.0-29.7 | ||||
| 60-69 | 446 (6.7) | 33 (24.3) | 8.4 | 20.4 | 8.6-48.7 | ||||
| 70+ | 363 (5.5) | 47 (34.6) | 14.9 | 36 | 15.3-84.1 | ||||
| Sex | |||||||||
| Female | 930 (14.0) | 5 (3.7) | 0.6 | 1 | Ref | ||||
| Male | 5694 (86.0) | 131 (96.3) | 2.7 | 4.4 | 1.8-10.8 | 2.6 | 1.0-6.4 | ||
| Race | |||||||||
| White | 5499 (83.0) | 124 (91.2) | 2.7 | 1 | Ref | ||||
| Black | 543 (8.2) | 8 (5.9) | 1.8 | 0.7 | 0.3-1.4 | 0.8¶ | 0.4-1.4 | ||
| Other/unknown | 582 (8.8) | 4 (2.9) | 0.8 | 0.3 | 0.1-0.8 | ||||
| Ethnicity | |||||||||
| Hispanic | 1199 (18.1) | 12 (8.8) | 1.2 | 1 | Ref | ||||
| Non-Hispanic | 5345 (80.7) | 123 (90.4) | 2.7 | 2.3 | 1.2-4.1 | 0.6 | 0.4-1.2 | ||
| Unknown | 80 (1.1) | 1 (0.7) | 1.6 | 1.3 | 0.2-12.2 | ||||
| Severity | |||||||||
| Mild | 4720 (71.3) | 94 (69.1) | 2.3 | 1 | Ref | ||||
| Moderate | 1904 (28.7) | 42 (30.9) | 2.7 | 1.1 | 0.9-1.9 | 0.9 | 0.6-1.3 | ||
| Inhibitor | |||||||||
| No | 6453 (97.4) | 133 (97.8) | 2.4 | 1 | Ref | ||||
| Yes | 171 (2.6) | 3 (2.2) | 2 | 0.8 | 0.3-2.6 | 0.7 | 0.2-2.3 | ||
| Hepatitis B | |||||||||
| No | 6519 (98.4) | 133 (97.8) | 2.4 | 1 | Ref | ||||
| Yes | 105 (1.6) | 3 (2.2) | 3.3 | 1.4 | 0.4-4.3 | 0.3 | 0.1-1.0 | ||
| Hepatitis C | |||||||||
| No | 6001 (90.6) | 78 (57.4) | 1.5 | 1 | Ref | ||||
| Yes | 623 (9.4) | 58 (42.7) | 10.8 | 7 | 5.0-9.8 | 2.2 | 1.5-3.1 | ||
| HIV | |||||||||
| No | 6454 (97.4) | 114 (83.8) | 2.1 | 1 | Ref | ||||
| Yes | 170 (2.6) | 22 (16.2) | 15.2 | 7.3 | 4.6-11.5 | 3.6 | 2.2-6.0 | ||
| FVIII exposure# | |||||||||
| No | 555 (8.4) | 3 (2.2) | |||||||
| Yes | 5122 (77.3) | 99 (72.8) | |||||||
| Unknown | 947 (14.3) | 34 (25.0) | |||||||
N/A; not available; Ref, reference group.
Mortality rate in deaths per 1000 person-years.
Based on 6401 persons with NSHA after excluding those with unknown status for ethnicity and/or race.
Age refers to the age at 12/31/2018 or age at death or age at termination.
Age (10-year increase).
Because there were no deaths in the 0 to 9 year age group, the next age group was used as the reference group for relative risk of death for the age characteristics.
Race (all others vs White).
Mortality rate and risk ratio was not calculated for FVIII exposure because of missing data.